Publications
Research that advances evidence, methods, and reimbursement decision-making.
A selection of peer-reviewed publications from our team spanning health technology assessment policy, evidence synthesis, comparative effectiveness, health economics, real-world evidence, and market access—including research informed by [hta]DataMine™ and other applied evidence programs.
J Comp Eff Res
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience.
Balijepalli C, Gullapalli L, Prasad S, Paul Roc N, Rusu A, Price N, Dempster W, Barakat S.
2025; 3250024. DOI: 10.57264/cer-2025-0024
Value in Health
Estimating Epidemiological Estimates of Rare Diseases in Reimbursement Submissions to Canada's Drug Agency: A Comparison of Approaches in the Absence of Local Real-World Data.
Druyts E, Gullapalli L, Balijepalli C.
2025; 28(6). DOI: 10.1016/j.jval.2025.04.543
J Comp Eff Res
The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health.
Balijepalli C, Gullapalli L, Joshy J, Rawson NB.
2024; 13(5): e230178. DOI: 10.57264/cer-2023-0178
Value in Health
Is There Value in Utilizing Country-Specific Health Utility Values for Health Technology Assessment Submissions? Findings From a Case Study in Hematological Cancers.
Yan K, Druyts E, Gullapalli L, Sharma A, Balijepalli C.
2024; 27(12): S360. DOI: 10.1016/j.jval.2024.10.1863
Value in Health
A Review of Real-World Evidence in Non-Oncology Submissions Made to Four Health Technology Assessment (HTA) Agencies.
Balijepalli C, Li J, Ferrazzi S, Mathers E, Gullapalli L, Awan A.
2024; 27(6): S253–254. DOI: 10.1016/j.jval.2024.03.1401
Value in Health
Modeling Approaches in the Cost-Effectiveness Analysis of Cancer Treatments: A Review of Submissions Made to the Canadian Agency for Drugs and Technologies in Health.
Balijepalli C, Joshy J, Gullapalli L, Yan K.
2023; 26(6): S153. DOI: 10.1016/j.jval.2023.03.2490
Value in Health
Assessing Relationships Between the CADTH Revised ICERs and Unmet Need, Clinical Benefit, Price Reductions, and Listing Negotiation Timelines.
Balijepalli C, Li J, Ferrazzi S, Mathers E, Gullapalli L, Awan A.
2024; 27(6): S256–S257. DOI: 10.1016/j.jval.2024.03.1418
Value in Health
Type of Clinical Evidence and Its Impact on Price Reductions for Oncology Drugs: A Review of Reimbursement Submissions in Canada.
Balijepalli C, Gullapalli L, Yan K, Sharma A, Druyts E, Rawson N.
2024; 27(12): S387–388. DOI: 10.1016/j.jval.2024.10.1997
Clinicoecon Outcomes Res
Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the CADTH Common Drug Review.
Balijepalli C, Gullapalli L, Druyts E, Yan K, Desai K, Barakat S, Locklin J.
2020; 12: 445–457. DOI: 10.2147/CEOR.S264589
Full publication record
Additional senior team publications on policy topics and applied methodologies are indexed on PubMed.
Work with us.
Whether you're planning a first submission or preparing for reassessment, we'd be glad to talk.